Max Rosett Biography and Net Worth

CFO of Immunome

Max Rosett initially joined Immunome in October 2023 at the close of the company’s merger with Morphimmune. He previously served in roles of increasing responsibility as Morphimmune, concluding as Acting Chief Operating Officer. Prior to Morphimmune, Mr. Rosett was a Principal at Research Bridge Partners, a life science investment firm. He has also worked as a software engineer at Google, and he started his career at the Boston Consulting Group, where he served clients in the pharmaceutical industry. Mr. Rosett earned a M.S. in Computer Science from Georgia Institute of Technology and a B.A. in Mathematics from Yale University.

What is Max Rosett's net worth?: The estimated net worth of Max Rosett is at least $375,535.16 as of September 19th, 2024. Rosett owns 47,476 shares of Immunome stock worth more than $375,535 as of May 14th. This net worth estimate does not reflect any other assets that Rosett may own. Learn More about Max Rosett's net worth.
How do I contact Max Rosett?: The corporate mailing address for Rosett and other Immunome executives is , , . Immunome can also be reached via phone at 610-321-3700 and via email at investors@immunome.com. Learn More on Max Rosett's contact information.
Has Max Rosett been buying or selling shares of Immunome?: Max Rosett has not been actively trading shares of Immunome during the last ninety days. Most recently, Max Rosett sold 14,380 shares of the business's stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $16.01, for a transaction totalling $230,223.80. Following the completion of the sale, the chief financial officer now directly owns 47,476 shares of the company's stock, valued at $760,090.76. Learn More on Max Rosett's trading history.
Who are Immunome's active insiders?: Immunome's insider roster includes Jean Bienaime (Director), Jack Higgins (Insider), Robert Lechleider (Insider), Michael Lefenfeld (Director), Michael Rapp (Director), Max Rosett (CFO), Purnanand Sarma (CEO), Clay Siegall (CEO), Philip Tsai (CTO), and Bruce Turner (Insider). Learn More on Immunome's active insiders.
Are insiders buying or selling shares of Immunome?: In the last twelve months, Immunome insiders bought shares 9 times. They purchased a total of 418,262 shares worth more than $3,425,760.18. In the last twelve months, insiders at the sold shares 2 times. They sold a total of 17,904 shares worth more than $279,313.12. The most recent insider tranaction occured on March, 26th when CEO Clay B Siegall bought 137,100 shares worth more than $999,459.00. Insiders at Immunome own 8.6% of the company. Learn More about insider trades at Immunome.
Information on this page was last updated on 3/26/2025.

Max Rosett Insider Trading History at Immunome

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/19/2024	Sell	14,380	$16.01	$230,223.80	47,476

Max Rosett Buying and Selling Activity at Immunome

Immunome Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Today's Range

Now: $7.91

$7.84

$8.37

50 Day Range

MA: $7.71

$5.56

$9.34

2 Week Range

Now: $7.91

$5.15

$16.81

Volume

1,771,365 shs

Average Volume

914,968 shs

Market Capitalization

$688.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Max Rosett Biography and Net Worth

What is Max Rosett's net worth?

How do I contact Max Rosett?

Has Max Rosett been buying or selling shares of Immunome?

Who are Immunome's active insiders?

Are insiders buying or selling shares of Immunome?